# CompassHER2-pCR (NCT04266249)

> CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04266249
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: ECOG-ACRIN Cancer Research Group
- Conditions: Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Invasive Breast Carcinoma; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8
- Interventions: Docetaxel; Lumpectomy; Mastectomy; Nab-paclitaxel; Paclitaxel; Pertuzumab; Radiation Therapy; Trastuzumab; Trastuzumab Emtansine
- Enrollment: 2175
- Primary outcome: Recurrence-free survival (RFS)

## Indexed commentary on CompassHER2-pCR so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 45
- YouTube: 16
- Bluesky threads: 3
- Podcasts: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=compassher2-pcr-nct04266249

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04266249", "email": "<work email>"}; the inbox owner confirms by the emailed link.